NEW YORK (GenomeWeb) – Asuragen today announced it has received a clinical laboratory permit from New York state to offer the company's Xpansion Interpreter and miRInform Thyroid tests in the state.

The Austin, Texas-based firm can now offer the tests in all 50 states in the US, it said.

Xpansion Interpreter is a reflex test for fragile X carriers. It determines the total number of CGG repeats and number of AGG interruptions in the Fragile X Mental Retardation gene and can help determine the risk for potential parents of having a child with fragile X syndrome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.